News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNext InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Related Stories News Avantor India Appointed as Exclusive Distributor for Sartorius Filter Papers to Serve India’s Laboratory Consumables Sector News Multi-Billion-Dollar Global Sports Brand U.S. Polo Assn. Earns Global Awards and Recognitions Across Business, Sport, and Content Categories News Think Tank Report on China’s Role as a Peace Facilitator Released at 2026 Hong Kong Forum on Cooperation and Development News Neat Introduces Thinking Rooms with Agentic Deployment Management and Intelligent Framing News EKH Limited Announces Launch of Hong Kong IPO News Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus